Karnofsky Performance Status
"Karnofsky Performance Status" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
| Descriptor ID |
D017567
|
| MeSH Number(s) |
E05.318.308.980.438.475.456.500.500 N05.715.360.300.800.438.375.364.500.500 N06.850.520.308.980.438.475.364.500.500
|
| Concept/Terms |
Karnofsky Performance Status- Karnofsky Performance Status
- Performance Status, Karnofsky
- Status, Karnofsky Performance
- Karnofsky Performance Status Scale
- Karnofsky Scale
- Scale, Karnofsky
- Karnofsky Index
- Index, Karnofsky
|
Below are MeSH descriptors whose meaning is more general than "Karnofsky Performance Status".
Below are MeSH descriptors whose meaning is more specific than "Karnofsky Performance Status".
This graph shows the total number of publications written about "Karnofsky Performance Status" by people in this website by year, and whether "Karnofsky Performance Status" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Karnofsky Performance Status" by people in Profiles.
-
Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2288-2295.
-
A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):464-471.
-
Symptom resolution in infiltrating WHO grade II-IV glioma patients undergoing surgical resection. J Clin Neurosci. 2016 Sep; 31:157-61.
-
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016 Apr; 124(4):998-1007.
-
Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases. J Neurooncol. 2015 Sep; 124(3):429-37.
-
Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J Pain Symptom Manage. 2015 Apr; 49(4):680-9.
-
True petroclival meningiomas: results of surgical management. J Neurosurg. 2014 Jan; 120(1):40-51.
-
Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients. J Clin Neurosci. 2013 Oct; 20(10):1382-6.
-
Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.